TFF Pharmaceuticals, Inc. (TFFP)
NASDAQ: TFFP · IEX Real-Time Price · USD
2.730
-0.020 (-0.73%)
At close: Apr 30, 2024, 4:00 PM
2.750
+0.020 (0.73%)
After-hours: Apr 30, 2024, 4:00 PM EDT
TFF Pharmaceuticals Revenue
In the year 2023, TFF Pharmaceuticals had annual revenue of $733.87K with 48.02% growth. Revenue in the quarter ending December 31, 2023 was $114.33K, a -63.45% decrease year-over-year.
Revenue (ttm)
$733.87K
Revenue Growth
+48.02%
P/S Ratio
9.37
Revenue / Employee
$38,625
Employees
19
Market Cap
6.88M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 733.87K | 238.07K | 48.02% |
Dec 31, 2022 | 495.81K | 407.64K | 462.39% |
Dec 31, 2021 | 88.16K | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
IM Cannabis | 54.95M |
XWELL | 30.11M |
Clever Leaves Holdings | 17.42M |
Vivos Therapeutics | 13.80M |
Pulmatrix | 7.30M |
Plus Therapeutics | 4.91M |
TFFP News
- 1 day ago - TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering - GlobeNewsWire
- 1 day ago - TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting - GlobeNewsWire
- 15 days ago - TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions - GlobeNewsWire
- 4 weeks ago - TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 4 weeks ago - TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs - GlobeNewsWire
- 5 weeks ago - TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting - GlobeNewsWire
- 5 weeks ago - TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 5 weeks ago - TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire